Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.71 -0.07 (-0.42%)

Streaming Delayed Price Updated: 12:14 PM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy ↗

March 01, 2023

The FDA will not hold an advisory committee meeting for the company's gene therapy.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗

March 01, 2023

Via Benzinga

Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today? ↗

March 01, 2023

Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.

Via InvestorPlace

Novavax Stock Down On Concern Over Whether The Company Can Continue ↗

February 28, 2023

Novavax warns that it may not be able to continue as a company.

Via Talk Markets

Expert Ratings for Sarepta Therapeutics ↗

February 15, 2023

Via Benzinga

9 Analysts Have This to Say About Sarepta Therapeutics ↗

January 20, 2023

Via Benzinga

BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know ↗

December 22, 2022

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

November 03, 2022

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:

Via Benzinga

Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks ↗

March 01, 2023

Markets are trying to rise, and these companies are helping out.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 01, 2023

Via Benzinga

Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

March 01, 2023

Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market...

Via Benzinga

Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

SRPT earnings call for the period ending September 30, 2022.

Via The Motley Fool

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 01, 2023

It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript ↗

February 28, 2023

SRPT earnings call for the period ending December 31, 2022.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 28, 2023

Via Benzinga

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

February 17, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

January 06, 2023

These biotechnology stocks are pushing ahead with promising innovations.

Via The Motley Fool

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

January 05, 2023

From Catalent, Inc.

Via Business Wire

2 Top Healthcare Stocks to Buy for the Long Haul ↗

December 09, 2022

These two companies are just getting started.

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy ↗

November 28, 2022

Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.

Via Investor's Business Daily

Earnings Scheduled For November 2, 2022 ↗

November 02, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.